Orthocell (OCC) Stock Price, News & Analysis

Company Overview

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 669,530 shs
• Average Volume: N/A
• Market Capitalization: A$375.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OCC Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Orthocell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Orthocell investors own include Plug Power (PLUG), Viralytics (VRACY), Genetic Technologies (GTG) and GP Strategies (GPX).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Steel Works
• Current Symbol: ASX:OCC
• CIK: N/A
• Web: www.orthocell.com.au
• Phone: 61 8 9360 2888
• Fax: N/A
• Employees: 340
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$7.18 million
• Net Margins: -111.03%
• Pretax Margin: N/A
• Return on Equity: -214.01%
• Return on Assets: -25.04%

Debt

• Debt-to-Equity Ratio: 15.22
• Current Ratio: 4.34
• Quick Ratio: 5.07

Sales & Book Value

• Annual Sales: A$5.32 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 3.41
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 209,580,000
• Free Float: N/A
• Market Cap: A$375.52 million
• Optionable: Not Optionable
• Beta: 1.16